4.7 Article

Mesenchymal Stem Cells as a Biological Drug for Heart Disease Where Are We With Cardiac Cell-Based Therapy?

Journal

CIRCULATION RESEARCH
Volume 117, Issue 3, Pages 229-233

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.117.306306

Keywords

cell- and tissue-based therapy; clinical trial; chronic heart failure; heart disease; mesenchymal stem cells

Funding

  1. National Institutes of Health [R01HL110737, R01HL084275, R01HL094849, R01HL107110, UM1HL113460]
  2. Starr Foundation
  3. Soffer Family Foundation

Ask authors/readers for more resources

Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available